Literature DB >> 7958725

A new beta-adrenoceptor blocking agent derived from dehydrozingerone.

B N Wu1, C R Yang, J M Yang, I J Chen.   

Abstract

1. Dehydrozingeronolol (DZPN; 0.1, 0.5, 1.0 mg/kg, i.v.) produced a dose-dependent bradycardia response and a sustained pressor action in urethane-anesthetized normotensive rats. DZPN inhibited the tachycardia effects by (-)isoproterenol, but had no blocking effect on the arterial pressor responses induced by phenylephrine. 2. In in vitro study, DZPN antagonized (-)isoproterenol-induced positive chronotropic effects in guinea-pig isolated right atria and relaxation responses in rat isolated uterus horns. 3. DZPN causes mild direct cardiac depression at high concentrations without intrinsic sympathomimetic activity (ISA). 4. The order of potency of beta-adrenoceptor antagonists in competing for the [3H]dihydroalprenolol binding sites was (-)propranolol >> DZPN > or = atenolol.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7958725     DOI: 10.1016/0306-3623(94)90242-9

Source DB:  PubMed          Journal:  Gen Pharmacol        ISSN: 0306-3623


  1 in total

1.  Capsinolol: the first beta-adrenoceptor blocker with an associated calcitonin gene-related peptide releasing activity in the heart.

Authors:  I J Chen; J L Yeh; Y C Lo; S H Sheu; Y T Lin
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.